Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK will pay up to $593 million for commercialization and further development rights to SCYNEXIS' Brexafemme, a first-in-class oral antifungal. The transaction…
SCYNEXIS announced today that it has entered into an exclusive license agreement with GSK for the commercialization and further development of Brexafemme…
Oct 15, 2025: GSK + SCYNEXIS resolve MARIO disagreement. MARIO Phase 3 invasive candidiasis study to be wound down/terminated; $22M payment + $2.3M wind-down…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
GSK obtained an exclusive, royalty-bearing global license (ex-Greater China/Hong Kong/Taiwan) to commercialize and further develop Brexafemme (ibrexafungerp), a first-in-class oral triterpenoid antifungal, announced March 30, 2023 and closed May 12, 2023. SCYNEXIS received $90M upfront and was eligible for up to $503M in development, regulatory and commercial milestones (incl. $245.5M tied to invasive candidiasis and $242.5M in sales milestones) plus tiered high-single-digit to high-teens royalties. The deal's economics deteriorated after a September 2023 voluntary Brexafemme recall (beta-lactam cross-contamination) and a ~19-month FDA clinical hold on the Phase 3 MARIO invasive candidiasis trial. On October 15, 2025 GSK and SCYNEXIS resolved a dispute over restarting MARIO: the study was wound down and terminated and the invasive candidiasis program discontinued, with GSK paying SCYNEXIS a $22M resolution payment plus $2.3M for wind-down activities and no further MARIO-related milestones. The license otherwise remains in effect; GSK is focused on relaunching Brexafemme for vulvovaginal candidiasis (VVC) and recurrent VVC, with the NDA transfer to GSK targeted for end-2025 and FDA relaunch discussions anticipated in 2026 — meaning the deal's most valuable disclosed milestone tranche is now unachievable.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / SCYNEXIS, Inc. (this deal) | 2023 | $593M | — |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2023 deals · GSK plc deals · Infectious Disease deals